Bulletin #100

Tiered Biologics Reimbursement Policy

Effective August 15, 2018

- Effective August 15, 2018, Manitoba Health, Seniors and Active Living will be implementing a Tiered Biologics Reimbursement Policy.

- This Policy will ONLY apply to New Patients (biologic naïve) and Existing Patients that have previously been trialed and deemed unresponsive to biologic therapy as follows:

    - New Patients (biologic-naïve);

        - Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)

    - Existing Patients (ONLY those that have previously been trialed and deemed unresponsive to biologic therapy)

        - Currently on Tier 1* product → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)

        - Currently on Tier 2** product→ Fail → Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)

*NOTE: *Patients will not be permitted to switch from Inflectra, Brenzys or Erelzi to another infliximab or etanerecept product listed in Tier 1 and/or 2 if previously trialed and deemed unresponsive to therapy.*

**NOTE: *Patients will not be permitted to switch from Remicade or Enbrel to another infliximab or etanerecept product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*

Special Requests (Case-By-Case)

- To request special consideration for coverage on a case-by-case basis outside of this Policy, the clinician may write to the Provincial Drug Programs Review Committee (PDPRC), based upon the unique circumstances of the patient and alternative treatments tried.

- Additional information on the Provincial Drug Programs Review Process and requirements can be found at: https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf.

Tiered Biologics Reimbursement Policy Flowsheet

New Patients (Biologic-Naïve):

Existing Patients:



**NOTE: Patients will not be permitted to switch from Inflectra, Brenzys or Erelzi to another infliximab or etanerecept product listed in Tier 1 and/or 2 if previously trialed and deemed unresponsive to therapy.*

***NOTE: Patients will not be permitted to switch from Remicade or Enbrel to another infliximab or etanerecept product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*

Tier 1							
Product Name	Generic Name	Rheumatoid Arthritis (RA)	Ankylosing Spondylitis (AS)	Psoriasis (PO)	Psoriatic Arthritis (PsA)	Crohn's Disease (CD)	Ulcerative Colitis (UC)
Actemra	tocilizumab	X					
Brenzys	etanercept	X	X				
Cimzia	certolizumab pegol	X	X		X		
Cosentyx	secukinumab		X	X	X		
Entyvio	vedolizumab					X	X
Erelzi	etanercept	X	X				
Humira	adalimumab						X
Inflectra	infliximab	X	X	X	X	X	X
Orencia	abatacept	X					
Rituxan	rituximab	X					
Simponi	golimumab	X	X		X		X
Simponi IV	golimumab	X					
Taltz	ixekizumab			X			
Xeljanz	tofacitinib	X					
Tier 2							
Enbrel	etanercept	X	X	X	X		
Humira	adalimumab	X	X	X	X	X	
Kineret	anakinra	X					
Remicade	infliximab	X	X	X	X	X	X
Stelara	ustekinumab			X			

- Prescribing Criteria for all products noted above can be found on the online document: Part 3 Exception Drug Status EDS) here: https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf
- For information on Health Canada's review and recommendations, please see: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
- For Common Drug Review's review and recommendations, please see: https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/reports

Dermatology (Plaque Psoriasis)

Tier 1
Cosentyx (secukinumab)
Inflectra (infliximab)
Taltz (ixekizumab)
Tier 2
Enbrel (etanercept)
Humira (adalimumab)
Remicade (infliximab)
Stelara (ustekinumab)

Gastroenterology (Crohn's Disease)

Tier 1
Entyvio (vedolizumab)
Inflectra (infliximab)
Tier 2
Humira (adalimumab)
Remicade (infliximab)

Gastroenterology (Ulcerative Colitis)

Tier 1
Entyvio (vedolizumab)
Humira (adalimumab)
Inflectra (infliximab)
Simponi (golimumab)
Tier 2
Remicade (infliximab)

Rheumatology (Ankylosing Spondylitis)

Tier 1
Brenzys (etanercept)
Cimzia (certolizumab pegol)
Cosentyx (secukinumab)
Erelzi (etanercept)
Inflectra (infliximab)
Simponi (golimumab)
Tier 2
Enbrel (etanercept)
Humira (adalimumab)
Remicade (infliximab)

Rheumatology (Psoriatic Arthritis)

Tier 1
Cimzia (certolizumab pegol)
Cosentyx (secukinumab)
Inflectra (infliximab)
Simponi (golimumab)
Tier 2
Enbrel (etanercept)
Humira (adalimumab)
Remicade (infliximab)

Rheumatology (Rheumatoid Arthritis)

Tier 1
Actemra (tocilizumab)
Brenzys (etanercept)
Cimzia (certolizumab pegol)
Erelzi (etanercept)
Inflectra (infliximab)
Orencia (abatacept)
Rituxan (rituximab)
Simponi (golimumab)
Simponi IV (golimumab)
Xeljanz (tofacitinib)
Tier 2
Enbrel (etanercept)
Humira (adalimumab)
Kineret (anakinra)
Remicade (infliximab)

FREQUENTLY ASKED QUESTIONS

How will this change affect patients?

- The Tiered Biologics Reimbursement Policy will:
  - NOT require patients to switch from their existing therapy (if currently providing the expected response) and
  - ONLY apply to:
    - New patients (biologic-naïve) and
    - Existing patients that have previously been trialed and deemed unresponsive to biologic therapy.

- Prescribers would be required to try two (2) Tier 1 products before prescribing a Tier 2 product.

- Clients and prescribers will continue to have a wide choice over therapeutic selection and if required, clinicians may request special consideration for coverage on a case-by-case basis outside of the Policy via the Provincial Drug Programs Review Committee (PDPRC).

What is a Tier 1 and Tier 2 biologic product?

Tier 1 biologic products (for the indications noted) have been determined to be the most cost-effective agents which allows Pharmacare to achieve greater value for its publicly funded drug programs, treat more patients without increasing expenditures, and retain prescriber/patient choice.

Which biologic products are listed on Tier 1 and Tier 2?

A current list of Tier 1 and Tier 2 products can be found online at: http://www.gov.mb.ca/health/pharmacare/healthprofessionals.html
Clients and prescribers will continue to have a wide choice over therapeutic selection.

What if the prescriber would like to use a Tier 2 product before a Tier 1 product which is outside the biologics tiering policy?

Clinicians may request special consideration for coverage on a case-by-case basis outside of the biologics tiering policy via the Provincial Drug Programs Review Committee (PDPRC).

Information on this program can be found here: https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf

Pharmacy Line: (204) 786-8000 in Winnipeg or at 1-800-663-7774 outside Winnipeg
Public Inquiries: (204) 786-7141 in Winnipeg or at 1-800-297-8099 outside of Winnipeg TTY (204) 774-8618.
Information is also available at http://www.gov.mb.ca/health/pharmacare/healthprofessionals.html